Modulation of 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) activity in the equine placenta by pregnenolone and progesterone metabolites.

The study investigates the behavior of the enzyme 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) in horse placentas and how it’s influenced by progestagens, certain types of hormones. The research shows that the potency and activity of this enzyme are generally higher in term placentas compared to late gestation placentas, but no significant difference was statistically validated. Specific steroid compounds resulted in noncompetitive or mixed inhibition of the enzyme.

3 beta-HSD Activity Measurements

• The researcher’s objective was to gauge the level of activity of 3 beta-HSD in the horse placenta. In other words, to measure how actively this enzyme functions. This was carried out in eight late gestation placentas and seven term placentas collected during c-sections. An additional seven term placentas collected at birth were examined.
• The method used to assess this activity was a tritium release assay with [3alpha-3H] pregnenolone acting as substrate—essentially, a measurement tool relying on changes in radioactivity.

Kmapp and Vmax Comparisons

• In terms of biophysics, Kmapp refers to the apparent Michaelis constant—a measure indicating the concentration of substrate where the reaction rate is half its maximum (Vmax). In the study, the Kmapp and Vmax values recorded for term placentas were generally higher than for late gestation samples. However, the statistical analysis did not declare a significant difference. This suggests that this enzyme’s activity and potency might hinge on the stage of pregnancy, but not conclusively so.

Inhibition Studies

• Tests of inhibition were conducted on three term and three late gestation placenta samples. This was done using steroid concentrations that resembled blood plasma levels. Various compounds were used, two of which resulted in ‘noncompetitive’ or ‘mixed’ inhibition. This means these compounds reduced the enzyme’s performance either by blocking its activity or by combining with it to form an ineffective complex.
• However, the compound 20alpha-hydroxy-5alpha-pregnan-3-one displayed competitive inhibition. This means the compound competed with the substrate, in this case, pregnenolone, for binding with the 3 beta-HSD enzyme.